Pieris Pharmaceuticals' (PIRS) merger target Palvella Therapeutics dosed the first patient in the phase 3 trial of QTORIN 3.9% rapamycin anhydrous gel, a treatment for microcystic lymphatic malformations.
Microcystic LMs is a rare genetic disease where abnormal lymph vessels leak fluid and bleed, causing frequent infections and skin problems.
The main goal of the study is to measure the change in the severity of microcystic LMs after 24 weeks, Palvella said Thursday in a statement. The trial will involve about 40 participants ages 6 and older, the company said.
The gel has received the US Food and Drug Administration's breakthrough therapy, fast track and orphan drug designations, and Palvella got up to $2.6 million from the agency to support the study.
Palvella and Pieris Pharmaceuticals agreed in July to merge.
Price: 16.38, Change: -0.34, Percent Change: -2.00
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。